Overview

The development of bispecific antibodies opened a new avenue of therapeutic options in oncology. During this webcast, participants will review the current role of bispecific antibodies in treating patients diagnosed with cancer, as well as management strategies for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

1. Discuss the current indications of bispecific antibodies in oncology
2. Identify new and emerging clinical data regarding the role of bispecific antibodies in cancer treatment
3. Review the pharmacology and clinical challenges related to the use of bispecific antibodies
4. Describe management strategies for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome in the context of bispecific antibodies therapy